IART · XBRL financial data

Integra Lifesciences Holdings financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (IART's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	1,372	1,542	1,558	1,542	1,611	1,635
Cost of goods and services sold	521	598	587	657	728	804
Gross profit	851	—	—	—	—	—
Selling, general and administrative	595	637	616	657	717	700
Operating income (loss)	151	197	239	112	28	(493)
Interest income	9	7	12	17	20	18
Interest expense	72	50	50	51	71	86
Other income (expense)	4	19	12	4	4	(2)
Income tax expense (benefit)	(40)	46	33	13	(11)	(47)
Net income (loss)	134	169	181	68	(7)	(516)
Earnings per share, basic USD per share	1.58	2.00	2.18	0.85	(0.09)	(6.74)
Earnings per share, diluted USD per share	1.57	1.98	2.16	0.84	(0.09)	(6.74)
Weighted average shares, basic millions of shares	85	85	83	80	77	77
Weighted average shares, diluted millions of shares	85	85	84	80	77	77

Fiscal years (IART's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	470	513	457	276	246	235
Short-term investments	—	—	0	33	27	29
Accounts receivable	226	232	263	259	272	279
Inventory	310	317	325	390	429	493
Prepaid and other current assets	69	91	117	—	—	—
Total current assets	1,237	1,154	1,161	1,058	1,082	1,160
Property and equipment, net	288	312	311	340	406	444
Right-of-use asset	84	85	148	156	144	141
Goodwill	932	1,013	1,039	1,055	1,097	615
Total assets	3,615	3,782	3,890	3,782	4,037	3,602
Accrued liabilities	94	120	80	101	122	130
Total current liabilities	401	340	321	307	922	456
Lease liability, non-current	88	90	157	167	167	163
Total liabilities	2,100	2,098	2,085	2,194	2,492	2,559
Retained earnings	532	699	879	947	940	423
Total stockholders' equity	1,515	1,685	1,804	1,588	1,545	1,043
Total liabilities and equity	3,615	3,782	3,890	3,782	4,037	3,602
Common shares outstanding (cover page) millions of shares	84	83	82	78	77	78

Fiscal years (IART's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	134	169	181	68	(7)	(516)
Stock-based compensation	20	36	28	20	24	19
Net cash from operating activities	204	312	264	140	129	50
Purchases of property and equipment	39	48	42	67	104	81
Net cash from investing activities	(68)	(161)	(59)	(94)	(391)	(108)
Proceeds from issuing common stock	0	—	—	—	—	—
Share repurchases	100	0	125	275	52	0
Net cash from financing activities	122	(98)	(252)	(230)	238	28
Net change in cash	271	43	(57)	(180)	(30)	(11)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Integra Lifesciences Holdings	252	411	96*	77.8M	—	Q3 FY26 10-QSep 30, 2026
Establishment Labs Holdings	71	68	(17)*	29.8M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
NovoCure	97	193	23	116.9M	—	Q3 FY26 10-QSep 30, 2026
Biolife Solutions	24	not reported	6.3*	48.9M	—	Q2 FY26 10-QJun 30, 2026
SI-BONE	35	56	5.9*	45.1M	—	Q3 FY26 10-QSep 30, 2026
Embecta	215	272	42*	56.7M	—	Q3 FY26 10-QJun 30, 2026
Mimedx Group	121	62	3.9*	145.9M	—	Q3 FY26 10-QSep 30, 2026
CONMED	48	336	49*	29.8M	—	Q3 FY26 10-QSep 30, 2026
Alphatec Holdings	80	221	19*	155.1M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.